2026-04-13T01:29:03Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/111202025-10-24T10:33:53Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Coloretti, Irene author Genovese, Andrea author Teixeira, Pedro J. author Cherian, Anusha author LANDONI, Giovanni author Ferrer, Ricard author 2024-02-26T12:42:51Z 2024-02-26T12:42:51Z 2024-02-21 Angiotensina II; Shock sèptic; Vasopressors Angiotensin II; Septic shock; Vasopressors Angiotensina II; Shock séptico; Vasopresores Patients with septic shock who experience refractory hypotension despite adequate fluid resuscitation and high-dose noradrenaline have high mortality rates. To improve outcomes, evidence-based guidelines recommend starting a second vasopressor, such as vasopressin, if noradrenaline doses exceed 0.5 µg/kg/min. Recently, promising results have been observed in treating refractory hypotension with angiotensin II, which has been shown to increase mean arterial pressure and has been associated with improved outcomes. This narrative review aims to provide an overview of the pathophysiology of the renin-angiotensin system and the role of endogenous angiotensin II in vasodilatory shock with a focus on how angiotensin II treatment impacts clinical outcomes and on identifying the population that may benefit most from its use. http://hdl.handle.net/11351/11120 Xoc sèptic - Tractament Hipotensió arterial DISEASES::Bacterial Infections and Mycoses::Infection::Sepsis::Shock, Septic Other subheadings::Other subheadings::Other subheadings::/drug therapy DISEASES::Cardiovascular Diseases::Vascular Diseases::Hypotension ENFERMEDADES::infecciones bacterianas y micosis::infección::sepsis::choque séptico Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::hipotensión Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review